Telomeres and the end-replication problem: telomere mechanism

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

Definition

Category: Core structure

Also known as: telomeric repeats, TTAGGG repeats

Telomeres are the repetitive nucleotide sequences (TTAGGG in humans) and associated proteins that cap the ends of linear chromosomes, protecting them from degradation and from being mistaken for broken DNA. Because DNA polymerase cannot fully replicate the very end of a linear molecule (the end-replication problem), telomeres shorten a little with each round of division unless they are extended by telomerase.

Key points

Telomeres solve the 'end-protection problem': they hide the natural chromosome end from the DNA-damage response so it is not treated as a double-strand break.
The end-replication problem means somatic cells lose telomeric DNA with each division; this progressive shortening is the biological clock the field studies.
Telomere sequence and length are necessary context for every downstream node here: telomerase, shelterin, the T-loop, senescence, and ALT.

Sourcing

Standard telomere-biology reviews (Blackburn; de Lange). Review-level description.

Reference synthesis (tier 4); verification: review_level_2026-07-12.